Literature DB >> 11579237

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients.

I Sereti1, B Herpin, J A Metcalf, R Stevens, M W Baseler, C W Hallahan, J A Kovacs, R T Davey, H C Lane.   

Abstract

OBJECTIVE AND
DESIGN: In an attempt to determine the mechanisms underlying the CD4 T cell expansions in patients receiving intermittent interleukin (IL)-2, a cohort of 10 HIV infected patients were studied during a 5-day cycle of IL-2 to measure rates of apoptosis, the expression of activation markers in CD4 and CD8 T cell subsets and the serum levels of proinflammatory cytokines. All patients were receiving highly active antiretroviral therapy.
METHODS: Peripheral blood mononuclear cells were tested pre- and at the completion of IL-2 treatment with annexin V/7-AAD for the measurement of apoptosis. Phenotypic analyses of T lymphocytes were performed in parallel. Serum levels of interferon (IFN)gamma, granulocyte-macrophage colony stimulating factor, IL-6 and tumor necrosis factor (TNF)alpha were tested by enzyme-linked immunosorbent assay.
RESULTS: IL-2 increased the spontaneous apoptosis rates of CD4 and CD8 T lymphocytes (P = 0.003). Expression of HLA-DR, CD38 and CD95 increased on both CD4 and CD8 T lymphocytes whereas CD25 induction was observed exclusively on CD4 T cells. Significant increases of serum IL-6 and TNFalpha levels were noted in all patients whereas viral loads remained unchanged.
CONCLUSION: Administration of IL-2 for 5 days in HIV infected patients leads to enhanced apoptosis of both CD4 and CD8 T cells despite an eventual increase of the CD4 T cell count. A profound activation state with induction of activation markers on T cells and high levels of TNFalpha and IL-6 accompanies the increased apoptosis during the IL-2 cycle. These data suggest that the CD4 expansions seen in the context of intermittent IL-2 therapy are the net result of increases in both cell proliferation and cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579237     DOI: 10.1097/00002030-200109280-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.

Authors:  Irini Sereti; Hiromi Imamichi; Ven Natarajan; Tomozumi Imamichi; Meena S Ramchandani; Yunden Badralmaa; Steve C Berg; Julia A Metcalf; Barbara K Hahn; Jean M Shen; April Powers; Richard T Davey; Joseph A Kovacs; Ethan M Shevach; H Clifford Lane
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

2.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

3.  Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Authors:  S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; D A Cooper; S Emery
Journal:  HIV Med       Date:  2010-08-31       Impact factor: 3.180

4.  The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.

Authors:  Sarah W Read; Emily J Ciccone; Peter J Mannon; Michael D Yao; Cheryl L Chairez; Richard T Davey; Joseph A Kovacs; Irini Sereti
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

5.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

6.  Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection.

Authors:  Ven Natarajan; Richard A Lempicki; Irini Sereti; Yunden Badralmaa; Joseph W Adelsberger; Julia A Metcalf; Darue A Prieto; Randy Stevens; Michael W Baseler; Joseph A Kovacs; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

7.  Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.

Authors:  Brian O Porter; Jean Shen; Joseph A Kovacs; Richard T Davey; Catherine Rehm; Jay Lozier; Gyorgy Csako; Khanh Nghiem; Rene Costello; Henry Clifford Lane; Irini Sereti
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

8.  CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis.

Authors:  Marcella Potestio; Pietro D'Agostino; Giuseppina Colonna Romano; Salvatore Milano; Viviana Ferlazzo; Alessandra Aquino; Gloria Di Bella; Rosalba Caruso; Giuseppe Gambino; Giustina Vitale; Serafino Mansueto; Enrico Cillari
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

9.  CD4 T Cells Treated with gp120 Acquire a CD45R0+/CD45RA+ Phenotype.

Authors:  Sergey A Trushin; Gary D Bren; Andrew D Badley
Journal:  Open Virol J       Date:  2009-04-01

10.  Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels.

Authors:  E J Ciccone; S W Read; P J Mannon; M D Yao; J N Hodge; R Dewar; C L Chairez; M A Proschan; J A Kovacs; I Sereti
Journal:  Mucosal Immunol       Date:  2009-12-02       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.